awmsg logo



dupilumab (Dupixent®)


Reference No. 4089


Appraisal information

dupilumab (Dupixent®) 300 mg solution for injection
dupilumab (Dupixent®) 200 mg solution for injection


Company: Sanofi
BNF category: Skin
NMG meeting date: 09/10/2019
AWMSG meeting date: 13/11/2019
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years of age who are candidates for systemic therapy
AWMSG Secretariat Appraisal Report (ASAR)
Download
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download